Bracco Diagnostics

107 College Road East
Princeton, NJ 08540
USA
Phone: (877) 272-2269
Fax: (866) 272-1619
[email protected]
Visit Website
Product Categories:
Radiopharmaceuticals and Tracers, Contrast Media, Contrast Media Injectors

RELATED CONTENT

Requiring half the gadolinium dosage compared to other macrocyclic gadolinium-based contrast agents (GBCAs) in approved indications in the U.S., gadopiclenol also has the highest relaxivity compared to approved GBCAs1-7
News | Contrast Media

First Nationwide Use of Bracco's VUEWAY (gadopiclenol) Solution for ...

February 15, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time February 15, 2023
Read more
News | Contrast Media

Efficacy and Safety of Gadopiclenol with Contrast-enhanced MRI of the ...

February 6, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time February 06, 2023
Read more
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) application for 177Lu-rhPSMA-10.1.
News | Prostate Cancer

Blue Earth Therapeutics Announces U.S. FDA Clearance for ...

April 19, 2022 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 19, 2022
Read more
Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals
News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Supports Timely Consideration and Passage of ...

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
Read more
Winship Cancer Institute of Emory University’s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint
News | Radiation Therapy

Results Published for Axumin (Fluciclovine F 18) PET Imaging Study ...

May 25, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 25, 2021
Read more
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
News | PET Imaging

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 ...

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time January 18, 2021
Read more
Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging solutions in an immersive digital experience at the first all-virtual Radiological Society of North America (RSNA) annual meeting being held November 29 through December 5.
News | Contrast Media Injectors

Bracco Showcases Immersive Digital Experience at RSNA20

November 17, 2020 — Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging ...

Time November 17, 2020
Read more
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded the 2020 Bracco Diagnostics Inc./RSNA Research Scholar Grant to Brent D. Weinberg, M.D., Ph.D., and the 2020 Bracco Diagnostics Inc./RSNA Research Resident Grant to Evan DC Calabrese, M.D., Ph.D. These grants are made possible by Bracco Diagnostics Inc.’s support of the RSNA R&E Foundation.
News | Radiology Business

Researchers Awarded 2020 Bracco Diagnostics Inc./RSNA Research Grants

November 3, 2020 — The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded the 20 ...

Time November 03, 2020
Read more
Gadolinium based contrast dye in brain MRI
News | Contrast Media

Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco

January 17, 2020 — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading ...

Time January 17, 2020
Read more
Results were presented at RSNA19 for the comparison of ProHance (Gadoteridol) Injection, 279.3 mg/mL and Gadavist (gadobutrol) Injection in MRI of the brain (the TRUTH study)
News | Contrast Media

AI Software Confirms the Results of a Large Scale Comparison of ...

December 10, 2019 — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in ...

Time December 10, 2019
Read more
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now